Biocept

Q: What industry does Biocept belong to?

Biocept is in the industry of: Business Services General , Business Services

Q: What is Biocept competition?

Biocept top competitors include: Epic Sciences Inc , Agendia Inc , Biotheranostics Inc , Biological Dynamics Inc

Business Services · California, United States · 177 Employees

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector™ technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.Read More

Contact

Who is Biocept

Headquarters

9955 Mesa Rim Rd, San Diego, California, 92121, United States

Phone Number

(858) 320-8200

Website

www.biocept.com

Revenue

$63.4M

Stock Symbol

BIOC

Industry

Business Services General

Business Services

Is this data correct?

View contact profiles from Biocept

Top Competitors of Biocept

Epic Sciences Inc
74
$31.5M
1
Agendia Inc
211
$58M
2
Biotheranostics Inc
131
$19.1M
3
Biological Dynamics Inc
64
$19M
4
Sysmex Inostics Inc
80
$27.6M
5
Castle Biosciences Inc
342
$98.1M
6

Biocept Org Chart

Samuel Riccitelli

Chief Executive Officer, Int...

Phone

Philippe Marchand

Chief Operating Officer

Phone

Antonio Morales

Interim Chief Financial Offi...

Phone

View Email Formats for Biocept

Biocept Company Metrics

Company Insights

Employee Growth Rate

Funding

Funding DateApr 14, 2020

RoundShare Placement

Amount$10.3M

Investors

Funding DateMar 05, 2020

RoundShare Placement

Amount$6.6M

Investors

Funding DateMar 02, 2020

RoundShare Placement

Amount$9.2M

Investors

$96.8M

Total Funding Amount

$10.3M

Most Recent Funding Amount

Number of Funding Rounds

Biocept News & Media

Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). This first patient was seen at the UT Southwestern Medical Center, one of the largest and most respected hospitals in the nation. The FORESEE trial is a multicenter, prospective clinical trial expected to enroll 40 p
Mar 24, 2023
www.businesswire.com
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees. The inducement stock options have a grant date of February 28, 2023 and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4). The
Mar 1, 2023
www.businesswire.com
Biocept to Lay Off 35 Percent of Staff, Explore Strategic Alternatives | GenomeWeb
The company is hoping to preserve its cash runway and find a way to derive some value for its shareholders from its cerebrospinal fluid assay CNSide.
Jan 6, 2023
www.genomeweb.com
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of a
Jan 6, 2023
www.businesswire.com
Biocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call Transcript
Biocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call Transcript November 28, 2022 Operator: Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. And please note that this event is being recorded. I would now […]
Dec 25, 2022
news.yahoo.com